Content |
Biography
2015: Appointment of IBM Watson Health as the head
In 2015 Deborah DiSanzo headed IBM Watson Health, having come from Philips Healthcare company.
2018: Leaving from a position of the general manager of IBM Watson Health
In October, 2018 Deborah DiSanzo left a post of the director of IBM Watson Health after a series of failure projects in which this division was engaged.
Deborah DiSanzo will remain in IBM, having joined department of cognitive solutions (IBM Cognitive Solutions). The senior vice president of Cognitive Solutions and IBM Research John Kelly is appointed the new general manager of IBM Watson Health.
Replacement of the leadership happened in IBM Watson Health after numerous criticism of the technologies developed by this division. In particular, slaboeffektivny was a system for cancer therapy of IBM Watson for Oncology. In one of such cases the computer diagnosed to the 65-year-old man lung cancer after severe bleeding was detected in it. Watson offered the patient chemotherapy and medicine bevatsizumad. However this medicine is contraindicated to people with bleedings — it can cause heavy or fatal hemorrhage.
Medical errors — not the only problem of the Watson project. As experts note, all division of IBM which is engaged in artificial intelligence endures crisis and slowly moves to crash. At the end of May in it there were mass reductions. One of their reasons — that Watson does not make profit. According to some information, in IBM do not see perspective any more to be fixed in the market of services for health care. And instead of improving medical artificial intelligence, Watson Health focused on cooperation with insurance companies.
Deborah DiSanzo protected Watson Health, saying that IBM "knows about the analysis of medical data more, than someone in the world". The company is engaged in this work most longer, having saved up about 13 thousand clients, "who know our strengths on own experience", said in the letter which was sent to the staff of division.[1]